Last updated: 2026-09-07 07:20:20. Prices reflect the latest closing data and will resume updating on the next trading day. Stock price data is sourced from Massive.
GT Biopharma Inc. (GTBP) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $0.24, with a market capitalization of $12.77M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $0.23 to $1.37. This page covers its latest market performance, valuation, price trends and company information.
$12.77M | |
$0.26 | |
$591.99 | |
$0.23 | |
$0.25 | |
1.12M | |
-- | |
-- | |
$1.37 | |
$0.23 | |
2.03% | |
-- |
GT Biopharma Inc. (GTBP) last closed at $0.25 as of 2026-09-04 23:48:00, unchanged from the previous close of $0.25.
During the latest regular trading session, GTBP traded between $0.23 and $591.99, with a volume of 1.12M shares. The closing price was near the lower end and near the lower end of its 52-week range.
Over the past seven days, GT Biopharma Inc. (GTBP) moved from $0.31 to $0.24, representing a decline of 22.58% ($0.07).
The stock traded between $0.23 and $0.26 during the period. The latest price is near the middle of the 7-day range, indicating strong downward.
The average daily volume was 553.29 thousand shares, up versus the previous seven-day period, indicating higher trading activity.
Position in Range: 1.2%
GTBP is currently trading at $0.24, placing it 1.2% of the way from its 52-week low of $0.23 to its 52-week high of $1.37. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
GT Biopharma Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel immuno-oncology products in the United States. The company is engaged in discovering, developing, and commercializing therapeutics from its proprietary product platform across various disease areas, mainly focused on the treatment of cancer. Its TriKE (Tri-specific Killer Engager) platform offers immuno-oncology products designed to treat hematologic malignancies, sarcoma, and solid tumors.
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 1 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of GT Biopharma Inc. (GTBP) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.